TB-500

Overview and Mechanism of Action

TB-500, the research designation for thymosin beta-4 (Tβ4), is a 43-amino-acid ubiquitous intracellular peptide first isolated from bovine thymus tissue and subsequently identified as the most abundant member of the thymosin beta family — a group of small, highly conserved actin-sequestering proteins present in virtually every cell type in mammals. The peptide is encoded by a single-exon gene and is constitutively expressed at high intracellular concentrations (estimated at 200–500 μM) in platelets and many other cell types, with levels rising substantially following tissue injury, inflammation, and hypoxia.

The primary well-characterized molecular function of thymosin beta-4 is G-actin (monomeric, globular actin) sequestration. Within cells, dynamic remodeling of the actin cytoskeleton — the transition between G-actin monomers and F-actin (filamentous actin) polymers — governs fundamental cellular processes including migration, division, phagocytosis, and mechanosensing. Tβ4 binds G-actin in a 1:1 stoichiometry via its central LKKTET motif, maintaining a pool of unpolymerized actin available for rapid cytoskeletal remodeling upon directional signals. This regulatory function places Tβ4 at the center of cell migration biology, which in turn underlies the peptide's roles in wound healing, angiogenesis, and tissue repair.

Beyond actin sequestration, research has identified a constellation of additional molecular interactions for Tβ4. The peptide's LKKTET motif is shared with the integrin-linked kinase (ILK) binding domain; Tβ4/ILK interactions have been proposed to activate downstream survival signaling pathways including AKT/PKB and NF-κB, promoting cell survival and anti-apoptotic responses in ischemic tissue. Tβ4 has been shown to promote endothelial cell migration and tube formation in Matrigel angiogenesis assays, stimulate keratinocyte migration in scratch wound assays, and accelerate hair follicle progenitor cell activation. A secreted form of Tβ4 is released from platelets upon tissue injury and has autocrine/paracrine effects on surrounding stromal cells. The N-terminal tetrapeptide fragment of Tβ4, acetyl-SDKP (Ac-SDKP, also known as seraspenide), has its own distinct biology involving inhibition of hematopoietic stem cell proliferation and anti-inflammatory and anti-fibrotic effects, and is released from Tβ4 by prolyl oligopeptidase. For more in-depth reading on the research background of this peptide, see our /learn/tb-500 article.

Research History and Development

Thymosin beta-4 was first isolated by Low and colleagues from thymus tissue in the 1970s during research into thymic humoral factors regulating lymphocyte function. Its identification as an actin-sequestering protein came later, through the work of Safer, Bhattacharya, and colleagues in the 1990s, which represented a significant reconceptualization of the molecule's primary function. The RegeneRx Biopharmaceuticals corporation subsequently developed Tβ4 as a therapeutic candidate for wound healing applications, sponsoring clinical trials examining topical Tβ4 in corneal epithelial wound healing (a Phase 2 trial reported encouraging results in neurotrophic keratopathy) and dermal wound healing.

Pre-clinical research has examined Tβ4 in multiple injury and disease models including myocardial infarction (where cardiomyocyte survival and epicardial progenitor cell activation have been documented), spinal cord injury (neuronal survival and axon sprouting), traumatic brain injury, dermal wound closure, tendon repair, and muscle injury. The breadth of positive pre-clinical findings across tissue types is consistent with Tβ4's ubiquitous cellular expression and fundamental role in cytoskeletal biology.

Typical Research Parameters

In animal models of wound healing and tissue repair, Tβ4 has been administered at doses ranging from 1 mcg to 150 mcg per animal in rodent studies, via subcutaneous, intraperitoneal, topical, or intramuscular routes depending on the experimental endpoint. Myocardial infarction research has employed intraperitoneal doses of 150–1500 mcg/kg in rodent models post-ligation. Outcome measures vary by model but typically include wound closure rate, histological assessment of tissue organization, angiogenesis density (CD31 staining), inflammation biomarkers (cytokine panels), and in cardiac models, echocardiographic function and cardiomyocyte survival counts. In vitro studies use scratch wound assays, Boyden chamber migration assays, tube formation assays, and actin polymerization kinetics assays. For research use only.

Storage Requirements

TB-500 lyophilized powder should be stored at -20°C in sealed vials, protected from moisture and light. Upon reconstitution with sterile bacteriostatic water, solutions should be stored at 2–8°C and used within 28 days. The 43-amino-acid sequence is relatively stable compared to smaller peptides by virtue of its higher molecular weight and secondary structure, but is susceptible to deamidation of asparagine and glutamine residues and oxidation of methionine residues under adverse storage conditions. Avoid alkaline storage conditions and metal ion contamination. Peptide purity by HPLC should be verified before use in quantitative assays.

Safety Notes and Research Considerations

Thymosin beta-4's endogenous ubiquity, its presence at high concentrations in human platelets (and release at wound sites), and its history of investigation in clinical trials suggest a favorable safety profile relative to many research peptides. However, its promotion of cell migration and angiogenesis means that studies involving models where uncontrolled angiogenesis or migration could confound results (e.g., tumor biology models) require careful experimental design and appropriate controls. The anti-apoptotic signaling attributed to Tβ4/ILK interactions should be considered in cytotoxicity assay contexts. Researchers should distinguish between full-length Tβ4 (43 residues) and fragment preparations (such as TB-500 Fragment 17-23, which has a distinct biological profile focused on the actin-binding domain). All in vivo research must be conducted with appropriate ethics committee approval. This material is for research purposes only.